While well-established treatment paradigms in prostate cancer clearly establish the therapeutic approach of testosterone reduction and AR inhibition in prostate cancer, it has also been known for many years that supraphysiologic levels of testosterone can paradoxically inhibit prostate cancer growth, pointing to a possible tumor suppressor function of AR activity in certain circumstances. The gene discussed is AR; the disease is prostate carcinoma.